CellGenic manufactures sequence-verified research peptides under cGMP conditions for licensed physicians, clinics, and laboratories. Expansion to Panama is planned for 2026, and providers in Panama may apply for provider access ahead of launch.
CellGenic’s verified-provider platform currently ships to Mexico, Argentina, Colombia, and Perú under local license, with expansion to Panama planned for 2026. Access to product information, documentation, and pricing is limited to verified physicians, clinic operators, and laboratory professionals who complete CellGenic’s provider-verification process.
This page is an educational reference for that provider community. It describes how CellGenic’s research peptides are classified, manufactured, and documented, and it summarizes the evidence base behind the peptide categories most frequently requested by clinics and laboratories in Panama. It does not describe dosing, administration, or use in humans or animals. All CellGenic peptide products are supplied strictly for laboratory and research use, and any application beyond that is the responsibility of the licensed professional who acquires them, governed by the regulatory framework applicable in their own jurisdiction.
Peptides are short chains of amino acids — typically under 50 residues — that occur naturally as signaling molecules throughout human and animal biology. Because a peptide’s sequence determines which cellular receptors it can bind, researchers can synthesize peptides that mimic, block, or modulate a specific biological pathway with more precision than a small-molecule drug typically allows. That precision is why peptides occupy a large and active share of current biomedical research: cellular signaling, metabolic regulation, tissue repair, and neurological function are all areas where synthetic peptides give laboratories a tool to isolate one mechanism at a time.
CellGenic supplies sequence-verified peptides to that research market. Each batch is manufactured against a defined specification and tested for identity and purity before release, with a Certificate of Analysis available to verified providers for product-authenticity review. The products described on this page are not drugs, foods, or cosmetics, are not approved for diagnostic or therapeutic use, and are not intended for administration to humans or animals. They are intended exclusively for in-vitro research, laboratory investigation, and formulation study by qualified professionals.
CJC-1295, ipamorelin, and tesamorelin — GHRH analogs studied for pulsatile growth-hormone release across endocrine and metabolic research.
NAD+ precursor formulations and AOD-9604, a growth-hormone fragment, studied in cellular-energy and lipid-metabolism pathways.
PT-141, a melanocortin-receptor agonist, and ARA-290, an erythropoietin-derived peptide studied for tissue-protective signaling.
Semax and Selank — synthetic heptapeptides from Russian neuropharmacology research, studied for neuroprotective and stress-response signaling.
Vial reconstitution, pen-based dosing precision, and intranasal absorption studied as separate formulation variables.
Peptide sequences are synthesized against a defined specification using controlled raw-material sourcing, with process parameters set to minimize batch-to-batch variation.
Products are purified and formulated — as lyophilized vials, pre-filled pens, or nasal-spray solutions — using standardized procedures that maintain identity, purity, and stability.
Each batch undergoes identity and purity testing, compiled into a Certificate of Analysis available to verified providers before use in their own research protocols.
Certificate of Analysis per batch
CellGenic’s platform is provider-gated: product specifications, documentation, and pricing are visible only after an applicant completes CellGenic’s verification process as a licensed physician, clinic, or laboratory. Verification is not based on self-attestation alone — it is reviewed by CellGenic’s team before catalog and pricing access is granted.
Providers remain responsible for ensuring that their acquisition, storage, and research use of any CellGenic peptide complies with the laws and professional standards that apply in their own jurisdiction. CellGenic’s role is limited to supplying documented, sequence-verified research material; it does not provide dosing guidance, protocols, or clinical instruction for human or animal use.
Verified providers can request a Certificate of Analysis for product batches, covering identity and purity testing performed as part of CellGenic’s release process.
The three formats represent different research and formulation contexts — vials for reconstitution-based protocols, pens for pre-filled dosing-consistency research, and nasal sprays for intranasal-delivery research. See the comparison above for detail.
Pricing, specifications, and Certificates of Analysis are visible to verified providers only. The listings below are a reference index of CellGenic’s current peptide portfolio in panama, organized by delivery format.
Pre-filled, ready-to-use formats developed for research into delivery consistency and dosing precision.
Aqueous peptide formulations supplied for intranasal-delivery and absorption-pathway research.
10mg/Oxytocin, 5mg Nasal Cellgenic
Verification unlocks CellGenic’s full peptide catalog, provider pricing, and Certificate of Analysis documentation for panama and CellGenic’s other markets.